The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: A sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide

Annals of Oncology

Volumn 15, Issue 10, 2004, Pages 1495-1503

  Portlock, C S ^a   Qin, J ^a   Schaindlin, P ^a   Roistacher, N ^a   Myers, J ^a   Filippa, D ^a   Louie, D ^a   Zelenetz, A D ^a   O'Brien, J P ^a   Moskowitz, C ^a   Norton, L ^a   Yahalom, J ^a   Straus, D J ^a   Bertino, J R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aggressive lymphomas; Dose dense; Dose intense; NHL 15; Non Hodgkin's lymphomas

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ANGIOSARCOMA; ARTICLE; ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; COLON DISEASE; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATURIA; HEMORRHAGIC CYSTITIS; HIGH RISK POPULATION; HOARSENESS; HUMAN; HYPOKINESIA; HYPOTHYROIDISM; IMMUNOBLASTIC LYMPHOMA; INFECTION; KIDNEY SARCOMA; LARGE CELL LYMPHOMA; LARYNX DISORDER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYELODYSPLASIA; MYOCARDIAL DISEASE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PARKINSON DISEASE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE DISEASE; SUDDEN DEATH; VOCAL CORD PARALYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 6944242554     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh390     Document Type: Article

References (15)

1. Schneider AM, Straus DL, Schluger AE et al. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high-grade nonHodgkin's lymphomas. J Clin Oncol 1990; 8: 94-102.
2. Fisher RI, Gaynor ER, Dahlberg S et al. Phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs. MACOP-B in patients with intermediate or high grade non-Hodgkin's lymphoma: results of SWOG 8516 (Intergroup 0067) the national high priority lymphoma study. N Engl J Med 1993; 328: 1002-1006.
3. Norton L, Simon R. The Norton-Simon Hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
4. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
5. Coiffier B. Increasing chemotherapy intensity in aggressive lymphomas: a renewal? J Clin Oncol 2003; 21: 2457-2459.
6. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
7. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244-1253.
8. The International Non-Hodgkin's Lymphoma prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Linch DC, Smith P, Hancock BW et al. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11 (Suppl 1): 87-90.
11. Pfreundschuh M, Trümper L, Kloess M et al. 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma: results of the completed NHL-B-2 trial of the DSHNHL. Blood 2002; 100 (Suppl 1): 774a.
12. Pfreundschuh M, Trümper L, Schmits R et al. 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: results of the completed NHL-B-1 trial of the DSHNHL. Blood 2002; 100 (Suppl 1): 110a.
13. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
14. O'Brien JP, O'Keefe P, Roistacher N et al. NHL-15 protocol for diffuse aggressive lymphomas: a dose intense regimen of doxorubicin, vincristine and cyclophosphamide. Blood 1992; 80: 157a.
15. O'Brien JP, O'Keefe P, Alvarez A et al. The Memorial Sloan-Kettering NHL-15 protocol for intermediate grade and immunoblastic lymphoma. Hem Onc Annals 1993; 1: 47-50.